Background/Aims: Des-γ-carboxyprothrombin (DCP), is a well-known tumor marker of hepatocellular carcinoma (HCC). On the other hand, some reports suggest that tissue expression of DCP is more useful as a prognostic factor than the serum DCP value. The aim of this study is to clarify the clinicopathological role of expression of DCP on HCC, especially when there is a low serum level of DCP. Methodology: Fifty-one patients with HCC who underwent curative hepatectomy were included in this study. Immunohistochemical staining was performed using anti-DCP monoclonal antibody, which was classified into 2 groups (strong and weak) by a pathologist. The immunohistochemical expression of tumor microvessel density (MVD) was evaluated using CD34 monoclonal antibody, and counted with specific staining of the capillary-like vessels in the tumor. The clinicopathological variables were compared between the strong and weak-staining groups. Results: A strong DCP expression was recognized in 31 patients. DCP expression was associated with tumor size (p<0.05) and portal vein infiltration (p<0.01). In addition, serum DCP levels and α-fetoprotein levels tended to be higher in the strong group. In 16 patients whose serum DCP level was <200mAU/ml, the recurrence-free survival rate was significantly lower in the strong group. No correlation was observed between DCP expression and MVD. Conclusions: DCP expression in HCC is useful for the prediction of early recurrence in patients with a low serum DCP level.
|Number of pages||5|
|Publication status||Published - Jul 2008|
All Science Journal Classification (ASJC) codes